We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
It would appear the market is beginning to operate as if a Biden administration will be entering the White House in January 2021. There are still some legal ripples flowing through vote counts, etc., but market indexes are bifurcated in a way they haven’t been in 20 years — literally. The last time we saw the Dow surge strongly ahead while the Nasdaq dipped into the red was back in 2000, when the tech bubble of the pre-Y2K market began to burst.
This is not to suggest any sort of “burst” is inevitable for tech stocks going forward, regardless who is president next year. But with knowledge that social media and e-commerce giants are expected to be prodded and poked under Biden, in order to determine whether Alphabet (GOOGL - Free Report) , Facebook , Amazon (AMZN - Free Report) and the rest are operating as relative monopolies, the way Ma Bell was broken up into an entire domestic telecommunications in the early 80s.
Of course, the sudden rotation out of “stay at home” equities like Zoom Video (ZM - Free Report) and Netflix (NFLX - Free Report) on the news about Pfizer’s (PFE - Free Report) Covid vaccine candidate basically being ready for market has brought a bigger contrast than normal to this bifurcation. The same goes for the sudden surge in oil and gas companies like ConocoPhillips (COP - Free Report) , which had been lain relatively dormant during the depths of the pandemic. Thus, the Dow is up 130 points a half-hour before Tuesday’s opening bell, while the tech-heavy Nasdaq is -150 points.
Eli Lilly (LLY - Free Report) is the latest pharma major to get good news on its Covid-19 treatment efforts: its antibody treatment, known currently as bamlanivimab (marketing title yet to come), has been approved for emergency use by the FDA. It is not a vaccine for Covid-19, but helps limit the severity of coronavirus cases in adult patients who display mild symptoms. President Trump was treated with bamlanivimab during his hospital stay at Walter Reed when he contracted the disease. The treatment generates monoclonal antibodies which assist one’s immune system to fight off the virus. Shares of Lilly are up 4% in early trading.
D.R. Horton (DHI - Free Report) put the strengthening housing market on display with its fiscal Q4 earnings results reported this morning. Earnings of $2.24 per share were well out in front of the $1.76 expected, up 66% year over year, on revenues of $6.4 billion beating the Zacks consensus by 8%, and up 27% year over year. The improving market has also led D.R. Horton to raise its guidance and dividend yield. Shares are up 3% in today’s pre-market.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Reopening Stocks Gain on Vaccine Hopes
It would appear the market is beginning to operate as if a Biden administration will be entering the White House in January 2021. There are still some legal ripples flowing through vote counts, etc., but market indexes are bifurcated in a way they haven’t been in 20 years — literally. The last time we saw the Dow surge strongly ahead while the Nasdaq dipped into the red was back in 2000, when the tech bubble of the pre-Y2K market began to burst.
This is not to suggest any sort of “burst” is inevitable for tech stocks going forward, regardless who is president next year. But with knowledge that social media and e-commerce giants are expected to be prodded and poked under Biden, in order to determine whether Alphabet (GOOGL - Free Report) , Facebook , Amazon (AMZN - Free Report) and the rest are operating as relative monopolies, the way Ma Bell was broken up into an entire domestic telecommunications in the early 80s.
Of course, the sudden rotation out of “stay at home” equities like Zoom Video (ZM - Free Report) and Netflix (NFLX - Free Report) on the news about Pfizer’s (PFE - Free Report) Covid vaccine candidate basically being ready for market has brought a bigger contrast than normal to this bifurcation. The same goes for the sudden surge in oil and gas companies like ConocoPhillips (COP - Free Report) , which had been lain relatively dormant during the depths of the pandemic. Thus, the Dow is up 130 points a half-hour before Tuesday’s opening bell, while the tech-heavy Nasdaq is -150 points.
Eli Lilly (LLY - Free Report) is the latest pharma major to get good news on its Covid-19 treatment efforts: its antibody treatment, known currently as bamlanivimab (marketing title yet to come), has been approved for emergency use by the FDA. It is not a vaccine for Covid-19, but helps limit the severity of coronavirus cases in adult patients who display mild symptoms. President Trump was treated with bamlanivimab during his hospital stay at Walter Reed when he contracted the disease. The treatment generates monoclonal antibodies which assist one’s immune system to fight off the virus. Shares of Lilly are up 4% in early trading.
D.R. Horton (DHI - Free Report) put the strengthening housing market on display with its fiscal Q4 earnings results reported this morning. Earnings of $2.24 per share were well out in front of the $1.76 expected, up 66% year over year, on revenues of $6.4 billion beating the Zacks consensus by 8%, and up 27% year over year. The improving market has also led D.R. Horton to raise its guidance and dividend yield. Shares are up 3% in today’s pre-market.